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Abstract
Background: Anti-thyroid antibodies (ATA), even if not associated with thyroid dysfunction, are
suspected to cause poorer outcome of in vitro fertilization (IVF).
Methods: We retrospectively analyzed: (a) the prevalence of ATA in euthyroid infertile women,
(b) IVF outcome in euthyroid, ATA+ patients, and (c) the effect of adjuvant treatments
(levothyroxine alone or associated with acetylsalicylic acid and prednisolone) on IVF results in
ATA+ patients. One hundred twenty-nine euthyroid, ATA+ women undergoing IVF were
compared with 200 matched, ATA-controls. During IVF cycle, 38 ATA+ patients did not take any
adjuvant treatment, 55 received levothyroxin (LT), and 38 received LT +acetylsalicylic acid
(ASA)+prednisolone (P).
Results: The prevalence of ATA among euthyroid, infertile patients was 10.5%, similar to the one
reported in euthyroid women between 18 and 45 years. ATA+ patients who did not receive any
adjuvant treatment showed significantly poorer ovarian responsiveness to stimulation and IVF
results than controls. ATA+ patients receiving LT responded better to ovarian stimulation, but had
IVF results as poor as untreated ATA+ women. Patients receiving LT+ASA+P had significantly
higher pregnancy and implantation rates than untreated ATA+ patients (PR/ET 25.6% and IR 17.7%
vs. PR/ET 7.5% and IR 4.7%, respectively), and overall IVF results comparable to patients without
ATA (PR/ET 32.8% and IR 19%).
Conclusion: These observations suggest that euthyroid ATA+ patients undergoing IVF could have
better outcome if given LT+ASA+P as adjuvant treatment. This hypothesis must be verified in
further randomized, prospective studies.
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Background
Autoimmune thyroid diseases are rather frequent in
women in the childbearing age, affecting 5-20% of them
[1]. They are characterized by the presence of anti-thy-
roglobulin and anti-thyroperoxidase antibodies, grouped
under the definition of anti-thyroid antibodies (ATA).
ATA are often detected in subjects complaining of hypo-
or hyperthyroidism, but are not rarely found in patients
without any sign of thyroid dysfunction [1].
Some evidence suggest that ATA could exert a negative
influence on the female reproductive potential. Women
with no signs of thyroid dysfunction who were ATA+ risk
spontaneous miscarriage three- to five-folds more than
ATA-women [2]. Moreover, some studies reported a sig-
nificantly higher ATA prevalence in subfertile women
complaining of pelvic endometriosis [3,4], premature
ovarian failure (POF) [5,6], polycystic ovary (PCO) [7], or
hyperprolactinemia [8].
Some authors even reported an unexpectedly high ATA
prevalence in euthyroid women with a history of three or
more unsuccessful IVF cycles [9], and ATA-positivity was
found to be associated with a low pregnancy rate in IVF
[10-12]. On the contrary, other studies failed to detect any
difference in IVF success rate between ATA+ and ATA-
women [13-15].
In our study, we analyzed the prevalence of ATA in infer-
tile women and compared it with that observed in age-
matched, fertile controls. Further, we retrospectively ana-
lyzed IVF outcome in euthyroid ATA+ women and com-
pared it with ATA-controls. Differently from previous
reports, we also studied the effect of some adjuvant med-
ical treatments that are frequently given to ATA+ women
during IVF (levothyroxine alone or associated with acetyl-
salicylic acid and prednisolone), on IVF results. Levothy-
roxine (LT), in fact, is claimed to reduce ATA level [16]
and lower the risk of miscarriage in ATA+ women [17],
whereas acetyl-salicylic acid (ASA) plus prednisolone (P)
was reported to improve IVF outcome in women with
autoimmune disorders [18-21]. Aim of the present study
is to check the effectiveness of such adjuvant treatments as
tools to improve IVF outcome in ATA+ patients.
Methods
Patients
Our retrospective analysis included 3076 infertile women
referring to the IVF Unit between February 2004 and May
2008. The diagnostic workout included anti-thyroglobu-
lin and anti-thyroperoxidase antibodies (ATA) detection,
as well as the assessment of circulating TSH, f-T4 and f-T3
levels. According to our guidelines, a woman was consid-
ered ATA+ when the antibody level reached 40 UI/mL for
anti-thyroglobulin and 35 UI/mL for anti-thyroperoxi-
dase antibodies respectively; patients with lower levels
were considered ATA-.
Among all patients, 42 resulted to be affected by hypo- or
hyperthyroidism and were excluded from the study; 3034
women were euthyroid, and among them 319 were ATA+.
One hundred twenty-nine euthyroid, ATA+ women
entered the IVF program and were further subdivided into
three subgroups: a) those who were not taking any adju-
vant medication at the time IVF (group A, n = 38), b)
those who despite being euthyroid received levothyroxine
(LT, 50 mcg/d) as adjuvant treatment during IVF (group B,
n = 55), and c) those who despite being euthyroid
received LT, acetyl-salicylic acid (ASA) and prednisolone
(P) as adjuvant treatment during IVF (group C, n = 36).
Adjuvant treatments were prescribed by different endo-
crinologists taking care of the patients' thyroid conditions
(not belonging to our team) without any known selection
criteria apart from their personal, clinical experience. As
controls, we considered 200 euthyroid, ATA- patients who
underwent IVF in the same period and had oocyte
retrieval the same day of the ATA+ women (group D).
The 329 patients (129 cases and 200 controls) included in
the study underwent 352 IVF cycles (52 in group A, 56 in
group B, 44 in group C, 200 in group D) and obtained 95
pregnancies, with an overall pregnancy rate/cycle of 27%.
Sixteen pregnancies subsequently aborted, and the overall
abortion rate was 16.8%.
ATA assay
Anti-thyroglobulin and anti-thyroperoxidase antibodies
were measured by Pharmacia Diagnostic commercial kits
(Pharmacia, Sweden) using an immunofluorescence
assay, with normal values set at < 40 UI/ml (anti-thy-
roglobulin) and < 35 U/ml (anti-thyroperoxidase).
IVF procedure
Superovulation was induced using a standard "long" pro-
tocol with GnRH agonist (Buserelin) plus gonadotropins
(rFSH or hMG) at appropriate doses (100-450 IU), that
were estimated according to the woman's age, antral folli-
cle count and basal (day 3) FSH. Ovarian response to
gonadotropins was monitored by transvaginal ultrasound
plus serum E2 measurement every third day from day 7 of
stimulation. The final follicle maturation was triggered by
giving 10,000 IU hCG i.m or s.c. when the leading follicle
reached 18 mm, with appropriate serum E2 levels.
Transvaginal ultrasound-guided oocyte aspiration (OPU)
was performed approximately 36 hrs after hCG injection
under local anaesthesia (paracervical block). Either IVF or
ICSI were performed according to the clinical indication.
According to Italian legal rules, a maximum number of
three oocytes were inseminated and unselected embryosReproductive Biology and Endocrinology 2009, 7:137 http://www.rbej.com/content/7/1/137
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were transferred into the uterus (ET) after 48 hours of in
vitro culture. The luteal phase was supplemented by vagi-
nally administered natural progesterone (400 mg/d).
After 14 days from ET, serum hCG was assayed and preg-
nancy was eventually confirmed by transvaginal ultra-
sound.
Adjuvant medical treatments
Patients in groups A (ATA+, no adjuvant treatment) and D
(ATA-) received a standard IVF treatment as described
above, without any adjuvant medication.
ATA+ patients treated with LT (group B) received LT 50
mcg/d orally throughout the whole IVF cycle, from the
first day of stimulation to the day of the pregnancy test.
Patients who had a positive pregnancy test and a clinically
confirmed pregnancy continued LT until 10 weeks of ges-
tational age. After this time, the option to continue LT
treatment was left to doctors taking care of the pregnancy.
ATA+ patients treated with LT, ASA and P (group C)
received a daily dose of 100 mg orally administered ASA +
10 mg P from the first day of stimulation; P was increased
to 30 mg/d for 5 days starting the day of ET, and subse-
quently returned to 10 mg/d until the day of hCG test.
This ASA+P protocol was previously published by our
group and proven to be safe in IVF patients [22]. Patients
of group C with a positive pregnancy test and a clinically
confirmed pregnancy continued the LT+ASA+P regimen
until 10 weeks of gestational age. After this time, the
option to continue the treatment was left to doctors taking
care of the pregnancy.
Statistics
The following variables were recorded: stimulation
length, total gonadotropin dose, number of retrieved
oocytes, ovarian responsiveness to stimulation (gonado-
tropin dose/retrieved oocyte), fertilization rate, number
of transferred embryos/cycle, pregnancy rate (PR)/started
cycle, PR/OPU, PR/ET, abortion rate, ongoing pregnancy
rate/ET.
The comparison among groups was performed using JMP
software [23]. Since variables were found to be normally
distributed at Lilliefors test, the ANOVA test, χ2 test and
Fisher's exact test were used.
Results
Prevalence of ATA in euthyroid, infertile women
The prevalence of ATA among euthyroid, infertile patients
was 10.5% (319/3034). Patients with pelvic endometrio-
sis or reduced ovarian reserve had significantly higher ATA
prevalence (21.8% and 22.5%, respectively, p < 0.01) if
compared to women with tubal disease (5.6%) or belong-
ing to couples with idiopathic infertility (13.9%) or male-
related infertility (6.4%).
The prevalence of PCO was similar in ATA+ and ATA-
patients (13.5% vs. 19.3%, respectively, p = ns). Hyper-
prolactinemia was significantly more frequent among
ATA+ women (14.1% vs. 7.2%, p < 0.01).
ATA and IVF outcome
ATA+ and ATA- patients undergoing IVF had similar age,
BMI, PCO prevalence, smoke habit prevalence, basal FSH
levels, antral follicle count, TSH and fT4 levels (Table 1).
ATA+ patients receiving no adjuvant medical treatment
(group A) showed a significantly worse ovarian respon-
siveness to gonadotropins than ATA-women (group D),
needed a higher gonadotropin dose, had longer stimula-
tion times and finally retrieved less oocytes (Table 2).
Oocyte and embryo quality was worse in group A than in
group D, the former obtaining lower implantation, preg-
nancy and ongoing pregnancy rates (Table 2).
ATA+ women treated with adjuvant LT (group B) showed
a slightly better ovarian responsiveness to gonadotropins,
Table 1: Clinical characteristics of the patients included in the study
Group A Group B Group C Group D p
Patients 38 55 36 200 ns
Age (yrs) 37.0 +/- 3.5 35.1 +/- 4.1 35.7 +/- 3.8 36.6 +/- 3.6 ns
BMI 22.1 +/- 3.7 22.6 +/- 3.5 22.8 +/- 2.8 21.8 +/- 3.0 ns
PCO (%) 8 . 61 0 . 91 11 0 . 8 n s
Smoke (%) 10.5 9 8.5 12.3 Ns
FSH (UI/L) 7.3 +/- 2.2 7.3 +/- 2.5 6.7 +/- 1.8 7.1 +/- 2.5 Ns
Antral follicle count 5.8 +/- 3.1 6.7 +/- 3.4 6.9 +/- 3.5 7.0 +/- 1.9 Ns
TSH (mIU/L) 2.0 +/- 1.2 2.1 +/- 1.3 2.1 +/- 1.5 2.2 +/- 1.1 Ns
fT4 (pg/mL) 10.6 +/- 2.8 9.9 +/- 3.5 10.1 +/- 3.2 10.3 +/- 3.0 Ns
fT3 (pg/mL) 3.1 +/- 1.4 3.0 +/- 1.5 3.2 +/- 1.7 3.3 +/- 1.9 Ns
Group A: ATA+, untreated patients. Group B: ATA+ patients treated with LT adjuvant therapy. Group C: ATA+ patients treated with LT+ASA+P 
adjuvant therapy; Group D: ATA-controls.Reproductive Biology and Endocrinology 2009, 7:137 http://www.rbej.com/content/7/1/137
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needed a lower gonadotropin dose and obtained more
oocytes at OPU than untreated patients (group A) (Table
2). Anyway, their ovarian responsiveness to stimulation
was significantly poorer if compared to ATA-controls
(Table 2). The pregnancy and implantation rates were sig-
nificantly higher in group B than in group A, but still sig-
nificantly lower than in group D (Table 2).
The adjuvant treatment with LT+ASA+P (group C) was
associated with a significantly higher ovarian responsive-
ness to stimulation than the one observed with other
ATA+ patients (groups A and B)(Table 2). Actually, it was
similar to the one of ATA-controls (Table 2). The preg-
nancy, implantation and ongoing pregnancy rates in
group C were comparable to ATA- patients, and signifi-
cantly higher than those observed in groups A and B
(Table 2).
Interestingly, the abortion rate was significantly higher in
all ATA+ patients, and was unaffected by adjuvant treat-
ments (Table 2).
Discussion
Anti-thyroglobulin, anti-thyroperoxidase antibodies, or
both, are frequently detected in subjects with hypo- or
hyperthyroidism of autoimmune origin, and can also be
found in patients without any sign of thyroid disease.
According to some reports, ATA positivity in euthyroid
women could be linked to reproductive problems, such as
increased abortion rate or infertility [2].
In the population of euthyroid, infertile women that we
observed, the prevalence of ATA was 10.5%, comparable
to what reported in large population studies on euthyroid,
fertile women between 18 and 45 years (13.8%; 95% CI
7.6-19.9) [24]. Our observation, therefore, does not sup-
port the concept of a strong association between ATA
posotivity and female infertility. It must be remarked,
however, that we considered clinically relevant (poten-
tially able to affect fertility) only ATA levels above a given
threshold, whereas some reports on fertile women
included all levels of positivity.
We observed that some specific causes of female subfertil-
ity, such as pelvic endometriosis or reduced ovarian
reserve, are more frequently associated with ATA than
other infertility factors. The association between ATA and
pelvic endometriosis, indeed, was already reported [3,4];
it could be based on a common dysfunction of the
immune system, as there is abundant evidence of the link
between endometriosis and specific immunological fea-
tures [25]. Also premature ovarian failure (POF), that is
considerable an extreme form of reduced ovarian reserve,
is often associated with autoimmune disorders [26], and
anti-zona pellucida antibodies able to cross-react with
thyroid antigens have been detected in POF patients: they
could represent a link between POF syndrome and anti-
thyroid autoimmunity [27]. We also observed, in agree-
ment with other reports [8], an increased prevalence of
ATA in hyperprolactinemic women. PRL is known to exert
immunomodulatory effects that could lead to increased
Table 2: IVF outcome of the patients included in the study
Group A Group B Group C Group D
IVF cycles 52 56 44 200
Total Gn dose (IU) 3714 +/- 1499 c 3430 +/- 1722 3000 +/- 1358 b 2755 +/- 1216 a
Stimulation length (d) 12.3 +/- 2.1 12.2 +/- 2.5 11.4 +/- 1.6 b 11.5 +/- 1.8 b
OPU 50 55 44 200
Retrieved oocytes 6.5 +/- 4.3 7.9 +/- 5.4 10.7 +/- 6.4 b 8.7 +/- 5.2 b
Gn dose/oocyte (IU) 1028 +/- 1141 878 +/- 1045 448 +/- 520 b 539 +/- 796 b
Fertilization rate (%) 74.2 78.5 82.5 83.0
ET 40 45 39 177
Pregnancies 41 11 4 6 6
PR/started cycle (%) 7.7 c 19.6 31.8 b 33.0 b
PR/OPU (%) 8.0 c 20.0 31.8 b 33.3 b
PR/ET (%) 10.0 c 24.4 35.9 b 37.3 b
Implantation rate (%) 4.7 c 14.4 17.7 b 19.0 a
Abortions 134 8
Abortion rate (%) 25.0 27.3 28.5 12.0 a
Ongoing PR/OPU (%) 6.0 c 14.5 22.7 b 29.3 b
Ongoing PR/ET (%) 7.5 c 17.8 25.6 b 32.8 b
Group A: ATA+, untreated patients. Group B: ATA+ patients treated with LT adjuvant therapy. Group C: ATA+ patients treated with LT+ASA+P 
adjuvant therapy; Group D: ATA-controls.
a = p < 0.01 vs groups A, B and C
b = p < 0.01 vs groups A, and B
c = p < 0.01 vs group B and CReproductive Biology and Endocrinology 2009, 7:137 http://www.rbej.com/content/7/1/137
Page 5 of 6
(page number not for citation purposes)
autoreactivity of the immune system [28]. Differently, we
failed to confirm the previously reported observation [7]
of increased PCO prevalence among ATA+ women.
Observing IVF outcome, we noticed that it tended to be
noticeably poorer in ATA+ than ATA-women. ATA+
patients who did not take any adjuvant treatment
responded significantly worse to ovarian stimulation than
ATA-controls, their gonadotropin dose/retrieved oocyte
ratio (a reliable marker of ovarian responsiveness to stim-
ulation) being significantly higher. A normal responsive-
ness to ovarian stimulation in ATA+ women was
previously reported [29], but that study included only 16
ATA+ patients and unfortunately did not report their basal
FSH level, nor their antral follicle count, two variables that
deeply influence ovarian response to hormones.
We observed that the presence of ATA could have affected
also the oocyte and consequently the embryo deriving
from it; in fact, we recorded a lower fertilization rate, preg-
nancy and implantation rates in untreated ATA+ patients
vs. ATA-controls. Interestingly enough, Bussen found a
higher prevalence of ATA in infertile women with a his-
tory of three or more unsuccessful IVF attempts [9], and
other studies reported poorer IVF results in ATA+ patients
[10-12]. Other authors, however, failed to confirm the
existence of an association between ATA and IVF failure
[13-15]. The inconsistency in the reported results could be
linked to several factors, like different criteria of patient
inclusion in the study (e.g. only those with unexplained
infertility or all infertile patients), different ATA level
threshold needed to include a patient, different criteria to
chose the control group, etc.
We observed a significantly higher abortion rate after IVF
in ATA+ patients vs. ATA-controls. A similar finding was
already reported by others [10,14,15,30] and it is not sur-
prising since an increased abortion rate occurs in ATA+
women even after spontaneous conception [2].
ATA+ women who despite being euthyroid received a low
dose of LT during IVF showed a slightly higher ovarian
responsiveness to gonadotropins, but IVF outcome was
still significantly poorer in comparison to ATA- patients.
Some doctors use to give a low dose of LT to ATA-positive
euthyroid women because this treatment was reported to
reduce ATA level [16] and to lower the risk of miscarriage
in recurrent aborters who conceived spontaneously [17].
In our study, the abortion rate after IVF was not influ-
enced by LT, and IVF results were not relevantly improved;
this could be due to the high estradiol levels reached dur-
ing IVF (approximately ten folds higher than in the phys-
iological cycle) that could have induced high levels of
thyroxine binding globulin, in turn able to bind and par-
tially inactivate LT.
The adjuvant treatment with acetylsalicylic acid (ASA)
combined with prednisolone (P) is advised by some doc-
tors to patients with autoantibodies undergoing IVF; in
fact, it was reported to improve IVF outcome in women
with autoimmune disorders [18-21] or with recurrent
abortions [31]. Beneficial effects of this adjuvant treat-
ment on IVF outcome, however, were not confirmed
when patients without autoantibodies were studied
[22,32]. Our retrospective analysis shows that women
treated with LT+ASA+P showed a higher ovarian respon-
siveness to gonadotropins and higher pregnancy, implan-
tation and ongoing pregnancy rates than other ATA+
patients. Their IVF results were comparable to those
observed in ATA- subjects. LT+ASA+P treatment, however,
was unable to decrease the abortion rate, that remained
significantly higher than the one observed in women
without ATA. The advantage of giving LT+ASA+P to euthy-
roid ATA+ women could depend on the combination of
the immunomodulatory activity of LT and P with a better
ovarian and endometrial blood perfusion due to ASA
[33]. Prednisolone could also lower the local inflamma-
tory reaction to the ET catheter and facilitate implantation
through improving the tolerance of the immune system
toward the transferred embryos [34].
In conclusion, this retrospective study on euthyroid ATA+
women shows that: a) ATA-positivity in infertile women is
as frequent as in euthyroid fertile women of comparable
age; only in case of pelvic endometriosis, reduced ovarian
reserve, or hyperprolactinemia, ATA prevalence is signifi-
cantly higher than normal; b) ATA+ patients have signifi-
cantly worse IVF outcome when compared to ATA-
women; c) the adjuvant treatment with LT gives a slight
improvement of ovarian responsiveness to stimulation,
but has no benefit on IVF results; d) the adjuvant treat-
ment with LT+ASA+P significantly improves IVF outcome;
e) no adjuvant treatment decreases the abortion rate after
IVF.
The beneficial effect of LT+ASA+P adjuvant treatment on
IVF outcome observed herein in euthyroid, ATA+ patients,
together with its low potential risk [22], suggests its possi-
ble clinical, targeted application in this specific subgroup
of IVF patients. However, our findings need to be vali-
dated in prospective randomized investigations before the
application of LT+ASA+P adjuvant treatment is encour-
aged.
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